Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2083-2089

  Torigoe, Shoujiro ^a   Ogata, Yutaka ^b   Matono, Keiko ^a   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

5 fluorouracil; Apoptosis; Cell cycle; Irinotecan (CPT 11); Sequence dependency; Thymidylate synthase

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FLUOROURACIL; G1 PHASE; G2 PHASE; HUMANS; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 67650912124     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S and Gonzalez C: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14: 709-715, 1996. (Pubitemid 26085513)
2. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C and Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000. (Pubitemid 30727802)
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000. (Pubitemid 30162806)
5. Husain I, Mohler JL, Seigler HF and Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-546, 1994. (Pubitemid 24053198)
6. Mans DR, Grivicich I, Peters GJ and Schwartsmann G: Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 35: 1851-1861, 1999. (Pubitemid 29512319)
7. Cao S and Rustum YM: Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dosage. Cancer Res 60: 3717-3721, 2000. (Pubitemid 32204557)
8. Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL and Rustum YM: Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 10: 1121-1129, 2004. (Pubitemid 38198914)
9. Inoue Y, Tanaka K, Hiro J, Yoshiyama S, Toiyama Y, Eguchi T, Miki C and Kusunoki M: In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. Int J Oncol 28: 479-486, 2006.
10. Guichard S, Cussac D, Hennebelle I, Bugat R and Canal P: Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73: 729-734, 1997. (Pubitemid 127483072)
11. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y and Shirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 17: 968-973, 2006. (Pubitemid 43778988)
12. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B and Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786, 2007. (Pubitemid 350086481)
13. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Kperoralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J and Twelves C X-ACT Study Group: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 14: 1735-1743, 2003.
14. Twelves C: Xeloda Colorectal Cancer Group: Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large, phase III trials. Eur J Cancer 38(Suppl 2): S15-S20, 2002. (Pubitemid 34158853)
15. Chou TC and Talalay P: Quantitative analyses of dosage-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
16. Inoue Y, Miki C, Watanabe H, Hiro J, Toiyama Y, Ojima E, Yanagi H and Kusunoki M: Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line. J Gastroenterol 41: 1149-1157, 2006. (Pubitemid 46487205)
17. Guichard S, Hennebelle I, Bugat R and Canal P: Cellular interactions of 5-fluorouratil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676, 1998. (Pubitemid 28077825)
18. Pavillard V, Formento P, Rostagno P, Formento JL, Fischel JL, Francoual M, Etienne MC and Milano G: Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 15: 1315-1322, 1998. (Pubitemid 28511268)
19. 2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 56: 4430-4437, 1996. (Pubitemid 26330451)
20. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M and Schwartz GK: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT116 colon cancer monolayers and xenografts. Clin Cancer Res 7: 4209-4219, 2001. (Pubitemid 34044647)
21. Grivicich I, Regner A, da Rocha AB, Grass LB, Alves PA, Kayser GB, Schwartsmann G and Henriques JA: Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines. Oncol Res 15: 385-392, 2005.
22. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG and Bertino JR: Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 4: 1323-1330, 1998. (Pubitemid 28213346)
23. Hsueh CT, Kelsen D and Schwartz GK: UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 4: 2201-2206, 1998. (Pubitemid 28415668)
24. Ogata Y, Sasatomi T, Mori S, Matono K, Ishibashi N, Akagi Y, Fukushima T, Murakami H, Ushijima M and Shirouzu K: Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. Anticancer Res 27: 2605-2611, 2007. (Pubitemid 47227972)